SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves steep selloff and repeated tests of its yearly lows are drawing attention amid concerns about heavy debt, costly financing, refinancing needs and insider selling, alongside broader doubts about AI-infrastructure spending. Traders are split: bears see financing risks as a threat to growth, while bulls point to its backlog and AI partnerships and view the selloff as overdone; analyst upgrades and ARKs buying have not dispelled skepticism.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is drawing attention amid a semiconductor selloff, with traders focused on CEO Hock Tans warning that some AI investing resembles gambling and his comments about capital constraints. The remarks and worries about AI spending and financing have fueled bearish sentiment, while other traders see the pullback as a buying opportunity based on Broadcoms AI-chip growth; many also complain that the stock has lagged semiconductor peers.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a prolonged post-IPO selloff, with traders citing lockup expirations and insider-share supply, a TD Cowen price-target cut, and concerns about OpenAI customer concentration, scaling, and Nvidia competition. Bears see continued selling pressure, while bulls argue the decline is overdone and point to Cerebras AI-chip technology and backlog.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is drawing attention amid a steep selloff and worries that its debt-funded AI data-center expansion, heavy capital spending, and weak free cash flow may be difficult to finance as credit costs rise and inflation fuels rate concerns. Bears question whether its backlog and AI demand will translate into cash flow, while bulls argue Oracles cloud business and contracted demand make the pullback an opportunity.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is rebounding alongside semiconductor stocks after a steep, extended selloff, drawing dip buyers who see oversold conditions and continued AI-chip demand as support for a recovery. Others warn the bounce may be temporary, citing concerns about AI investment returns and debt, market uncertainty, and upcoming chip-sector earnings.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is drawing attention amid a sharp AI/neocloud selloff fueled by concerns about financing, debt exposure and whether infrastructure spending will earn adequate returns. Traders are divided over whether the rebound is an oversold relief move or a pause before further declines, with some arguing Nebius is better positioned than more leveraged peers.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is drawing attention amid a pullback and tentative rebound in AI and semiconductor stocks, as traders debate whether data-center spending can generate adequate returns and whether financing stress at firms such as CoreWeave signals broader risk. Bulls point to sustained chip demand and upcoming company updates, while bears remain concerned about AI valuations, debt exposure, and competition.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celesticas large equity offering has pressured shares, with traders citing dilution even as the capital is intended to support expansion. The selloff is being debated against the bullish AI and data-center demand outlook, prompting dip-buying while others remain concerned about volatility and the stocks valuation.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech and semiconductor rebound after the AI-related selloff has lifted QQQ, with traders debating whether it marks a durable recovery or a short-lived relief bounce. Upcoming megacap earnings and concerns about AI spending, oil prices, and inflation are keeping sentiment divided.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

JPMorgans upgrade of Intel to Neutral from Underweight, citing improving execution, is a key focus after a sharp selloff. Some traders see it as validation of the turnaround, while others dismiss the upgrade because the price target was unchanged; broader chip-sector weakness and unconfirmed foundry-deal speculation add to the debate.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DaVita Inc. Schedules 3rd Quarter 2026 Investor Conference Call

DaVita Inc. Schedules 3rd Quarter 2026 Investor Conference Call DaVita Inc. Schedules 3rd Quarter 2026 Investor Conference CallPR NewswireDENVER, Oct. 19, 2026 DENVER, Oct. 19, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announcedtoday that it will hold its quarterly conference call to discuss...

DaVita HealthCare (DVA) Stock Moves -1.01%: What You Should Know

DaVita HealthCare (DVA) closed at $187.25 in the latest trading session, marking a -1.01% move from the prior day.

DaVita Brings New Clinical Research to ASN Kidney Week 2026, Advancing Evidence for the Next Era of Kidney Care

DaVita Brings New Clinical Research to ASN Kidney Week 2026, Advancing Evidence for the Next Era of Kidney Care DaVita Brings New Clinical Research to ASN Kidney Week 2026, Advancing Evidence for the Next Era of Kidney CarePR NewswireDENVER, Oct. 15, 2026Seven studies spanning middle molecule...

Why DaVita HealthCare (DVA) Outpaced the Stock Market Today

In the latest trading session, DaVita HealthCare (DVA) closed at $179.25, marking a +1.26% move from the previous day.

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now

DaVita gains from IKC growth, improving treatment economics and stronger formulary adoption, but payer-mix pressures and costs remain concerns.

DaVita Activates Emergency Response Efforts Ahead of Hurricane Isaias, Urges Kidney Patients to Prepare Early

DaVita Activates Emergency Response Efforts Ahead of Hurricane Isaias, Urges Kidney Patients to Prepare Early DaVita Activates Emergency Response Efforts Ahead of Hurricane Isaias, Urges Kidney Patients to Prepare EarlyPR NewswireDENVER, Oct. 8, 2026Patients encouraged to confirm treatment...

Strength Seen in Option Care (OPCH): Can Its 32.7% Jump Turn into More Strength?

Option Care (OPCH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

DaVita HealthCare (DVA) Laps the Stock Market: Here's Why

In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $178.69, denoting a +1.33% move from the preceding trading day.

DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note

The latest trading day saw DaVita HealthCare (DVA) settling at $174.67, representing a -4.62% change from its previous close.

DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors

DaVita HealthCare (DVA) closed the most recent trading day at $193.86, moving +1.55% from the previous trading session.

DaVita, Inc. engages in the provision of medical care services. It operates through the US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives segments. The US Dialysis and Related Lab Services segment offer kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consists primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

DaVita Inc

Why Did DaVita Stock Jump 15% After Hours Today?

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>The company beat Q4 earnings and issued 2026 EPS guidance above consensus.</li><li>Q4 IKC adjusted operating income was $46 million, with full-year results lifted by stronger-than-expected shared savings from&nbsp;the final 2024 reconciliation.</li><li>DaVita expects flat treatment volumes in 2026, noting that a return to 2% or higher growth will depend on improved clinical outcomes.</li></ul><p>Shares of DaVita Inc. jumped about 15% in extended trading&nbsp;on Monday after the dialysis service provider topped fourth-quarter (Q4) earnings estimates and said its Integrated Kidney Care (IKC) unit hit profitability a year earlier than planned.</p><h2 class="st-heading-2"><strong>Earnings And 2026 Outlook Beat Expectations</strong></h2><p>DaVita reported Q4 adjusted earnings per share (EPS) of $3.40, beating consensus of $3.19, on revenue of $3.62 billion, also above estimates of $3.51 billion.&nbsp;</p><p>For 2026, the company forecast adjusted EPS of $13.6-$15, versus consensus of $12.74, along with adjusted operating income growth of $2.085 billion-$2.235 billion and free cash flow of $1-$1.25 billion.</p><h2 class="st-heading-2"><strong>Integrated Kidney Care Turns Profitable Ahead Of Plan</strong></h2><p>DaVita said IKC achieved full-year profitability in 2025, a year ahead of its original 2026 target. Q4 IKC adjusted operating income was $46 million, while full-year results benefited from stronger-than-expected shared savings tied to&nbsp;the final reconciliation of 2024 performance. The company said the milestone validates its clinical care model, contracting structure, and technology-enabled platform, and expects to deliver $20 million&nbsp;in incremental IKC operating income growth in 2026.</p><h2 class="st-heading-2"><strong>IKC Patients See Lower Costs, Better Survival</strong></h2><p>The company said IKC patients were 35% more likely to start dialysis with permanent vascular access and incurred three times lower costs in the first 180 days of treatment. The company cited fewer bloodstream infections, higher vaccination rates, better adherence, and fewer missed treatments.&nbsp;</p><p>Vaccinated patients&nbsp;had a 9% lower risk of hospitalization and a 27% lower risk of mortality. DaVita also said GLP-1 drugs and advanced dialysis technologies could reduce mortality over time.</p><h2 class="st-heading-2"><strong>DaVita Braces For ACA Hit, Eyes Medicare Boost</strong></h2><p>DaVita expects treatment volume to be roughly flat in 2026, noting that a return to 2% or higher growth will depend on improved clinical outcomes, with benefits likely to show up over the next couple of years. The company also flagged a $40 million headwind in 2026 from changes to ACA premium support, noting the impact is expected to increase in 2027 before easing thereafter.</p><p>At the same time, DaVita pointed to a potential tailwind in 2027, citing a 6% Medicare Advantage rate increase for end-stage renal disease (ESRD) patients. The company also announced a $200 million minority investment in Elara Caring&nbsp;to expand home-based care and reduce hospitalizations and missed treatments.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment for DaVita was ‘extremely bullish’ amid ‘extremely high’ message volume.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/dva_ss_png_06c11a7684.webp" alt="dva ss.png" width="974" height="143"><figcaption>DVA sentiment and message volume as of February 2 | Source: Stocktwits</figcaption></figure><p>One user said, “This appears way undervalued with those numbers. Single digit multiple to earnings.”</p><p><stembedurl>https://stocktwits.com/Chickenstick1/message/643737411</stembedurl></p><p>Another user called the update a “nice” earnings report.</p><p><stembedurl>https://stocktwits.com/MaverikIT/message/643738852</stembedurl></p><p><a href="https://stocktwits.com/symbol/DVA">DaVita’s stock</a> has declined 37% over the past 12 months.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the DaVita Inc company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

DaVita said its integrated kidney care unit hit full-year profitability in 2025, a year ahead of its original 2026 target. 

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$187.00
Prev Close	$187.31
Open	$185.19
Dividend Yield	0.00%
50-Day Moving Average	$180.55
Beta	0.38
Avg. Volume	718,085.90
PE Ratio	15.77

52-Week High	$247.49
52-Week Low	$101.00
Market Capitalization	$11.95B
EPS (Annual)	$9.51
Price to Book	-14.35
Revenue Per Employee	$174,911.14

Feed

News

Sentiment

Earnings

Fundamentals

Info

DVA Fundamentals